Importance Approximately one-third of patients with major depressive disorder (MDD) do not
respond to available antidepressants. Objective To assess the efficacy, safety, and dose …

Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral
antidepressants (ADs) is approved in the European Union, United States, and other markets …

ABSTRACT Introduction: In March 2019, intranasal esketamine was approved by the Food
and Drug Administration (FDA) for the treatment of treatment-resistant depression (TRD) in …

Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …

Objective: About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants. This study compared the efficacy and safety of …

This narrative review aims to provide an overview of the current literature on the
pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of …

Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, use
requirements, and place in therapy of esketamine for treatment-resistant depression (TRD) …

Objectives This is a meta-analysis of randomized double-blind controlled-placebo trials
(RCTs) examining the effectiveness, tolerability, and safety of intranasal esketamine in …

Objective: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new
oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). Methods …

Importance Controlled studies have shown short-term efficacy of esketamine for treatment-
resistant depression (TRD), but long-term effects remain to be established. Objective To …